Figure 3From: Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) surveyCurrent use of symptomatic treatments for fatigue based on the use of IMA. IMA = NARCOMS respondents treated with IMA;No IMA = NARCOMS respondents not treated with IMAs. 4-AP, 4-aminopyridine; IMA, immunomodulatory agents.Back to article page